Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective

BACKGROUND: Decompensated cirrhosis is a serious clinical complication of chronic hepatitis B (CHB) that places a large economic burden on the US health care system. Although entecavir has been shown to improve health outcomes in a cost-effective manner in mixed populations of CHB patients, the cost...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Naoky, Jeffers, Lennox, Cragin, Lael, Sorensen, Sonja, Su, Wenqing, Rosenblatt, Lisa, Tang, Hong, Hebden, Tony, Juday, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430439/
https://www.ncbi.nlm.nih.gov/pubmed/22977309
http://dx.doi.org/10.2147/CEOR.S31784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430439/
https://www.ncbi.nlm.nih.gov/pubmed/22977309
http://dx.doi.org/10.2147/CEOR.S31784

Ejemplares similares